Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.47 USD
Change Today +0.92 / 7.33%
Volume 777.3K
RGLS On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Open
$12.63
Previous Close
$12.55
Day High
$13.50
Day Low
$12.57
52 Week High
11/10/14 - $25.60
52 Week Low
05/9/14 - $5.40
Market Cap
680.7M
Average Volume 10 Days
903.8K
EPS TTM
$-1.12
Shares Outstanding
50.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGULUS THERAPEUTICS INC (RGLS)

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. The company’s clinical stage products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection; and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease. It has strategic collaborations with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases. The company also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 preclinical fibrosis program for the treatment of Alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

81 Employees
Last Reported Date: 02/19/15
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $618.0K
Chief Business Officer, General Counsel and S...
Total Annual Compensation: $244.7K
Chief Scientific Officer
Total Annual Compensation: $360.5K
Compensation as of Fiscal Year 2014.

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Inc. Selects RG-125 (AZD4076), GalNAc-Conjugated Anti-miR Targeting microRNA-103/107 for Treatment of Non Alcoholic Steatohepatitis in Patients with Type 2 Diabetes/Pre-Diabetes, as Clinical Candidate by AstraZeneca

Regulus Therapeutics Inc. announced the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of Non Alcoholic Steatohepatitis in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 (AZD4076) is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5 million and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 (AZD4076) program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 (AZD4076) in humans by the end of 2015.

Regulus Therapeutics Seeks Acquisitions

Regulus Therapeutics Inc. (NasdaqGM:RGLS) may use proceeds from offering to in-license, acquire or invest in complementary micro RNA businesses, technologies, products or assets.

Regulus Therapeutics Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 01:40 PM

Regulus Therapeutics Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $13.47 USD +0.92

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.86 AUD +0.075
Galena Biopharma Inc $1.37 USD +0.02
Marina Biotech Inc $0.56 USD -0.0099
Silence Therapeutics PLC 304.00 GBp -0.50
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 82.3x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 65.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit www.regulusrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.